Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neuroendocrine Tumors
Small Cell Carcinoma
Ovarian Epithelial Cancer

Interventions: Drug: Cisplatin
Drug: RRx-001
Drug: Carboplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Doxil
Drug: Irinotecan
Drug: Nab-Paclitaxel
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Taxane
Drug: Pemetrexed

First Posted Date: 2015-07-03

Last Posted Date: 2022-10-03

Lead Sponsor: EpicentRx, Inc.

Target Recruit Count: 139

Registration Number: NCT02489903

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Baptist Health, Lexington, Kentucky, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 7 locations

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Phase 1

Terminated

Conditions: Burkitt Lymphoma
CD20-Positive Neoplastic Cells Present
Indolent Non-Hodgkin Lymphoma
Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Clearing Agent
Drug: Cytarabine
Drug: Etoposide
Radiation: Indium In 111-DOTA-Biotin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Yttrium Y 90-DOTA-Biotin

First Posted Date: 2015-06-26

Last Posted Date: 2020-11-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT02483000

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Phase 1

Conditions: Adult Burkitt Lymphoma
MYC Gene Mutation
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
Plasmablastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Therapeutic Hydrocortisone
Drug: Vincristine Sulfate

First Posted Date: 2015-06-25

Last Posted Date: 2022-02-21

Lead Sponsor: Northwestern University

Target Recruit Count: 38

Registration Number: NCT02481310

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 2 locations

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: KPT-330
Drug: Rituximab
Drug: Etoposide
Drug: Carboplatin
Drug: Ifosfamide
Drug: Dexamethasone

First Posted Date: 2015-06-15

Last Posted Date: 2022-04-12

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 22

Registration Number: NCT02471911

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Other: Placebo Administration
Other: Pharmacogenomic Study

First Posted Date: 2015-05-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT02443077

Locations: 🇺🇸
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States
🇺🇸
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
🇺🇸
Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States

and more 279 locations

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Drug: Ibrutinib
Drug: Rituximab
Drug: Gemcitabine
Drug: Dexamethasone
Drug: Mesna
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Selinexor
Drug: G-CSF

First Posted Date: 2015-05-07

Last Posted Date: 2024-06-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 320

Registration Number: NCT02436707

Locations: 🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 11 locations

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1

Completed

Conditions: Solid Malignant Tumors
Osteosarcoma
Differentiated Thyroid Cancer (DTC)
Tumors

Interventions: Drug: Lenvatinib
Drug: Ifosfamide
Drug: Etoposide

First Posted Date: 2015-05-04

Last Posted Date: 2023-07-11

Lead Sponsor: Eisai Limited

Target Recruit Count: 117

Registration Number: NCT02432274

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇫🇷
Centre Oscar Lambret Lille, Lille, Rhone, France
🇫🇷
CHU de Toulouse - Hopital des Enfants, Toulouse, France

and more 16 locations